HCV Treatment
AASLD 2011: All-Oral Combination of BI 201335, BI 207127 and Ribavirin Shows Good Efficacy at 12 Weeks
- Details
- Category: HCV Treatment
- Published on Thursday, 01 December 2011 00:00
- Written by Liz Highleyman
An interferon-free triple regimen containing the hepatitis C virus (HCV) protease inhibitor BI 201335, the HCV polymerase inhibitor BI 207127, and ribavirin for 12 weeks suppressed viral load in three-quarters of previously untreated genotype 1 patients, according to findings from the SOUND-C trials presented at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) in San Francisco.
AASLD 2011: Predictors of Response to Boceprevir plus Pegylated Interferon/Ribavirin
- Details
- Category: HCV Treatment
- Published on Tuesday, 29 November 2011 00:00
- Written by Liz Highleyman
Low baseline viral load, hepatitis C virus (HCV) subtype 1b, and absent or mild liver damage predicted sustained response to treatment with boceprevir (Victrelis) plus pegylated interferon/ribavirin, researchers report at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) this month in San Francisco.
AASLD 2011: TMC435 + Interferon/Ribavirin Raises Cure Rates for Naive and Experienced Hepatitis C Patients
- Details
- Category: HCV Treatment
- Published on Friday, 18 November 2011 00:00
- Written by Liz Highleyman
Adding the HCV NS3/4A protease inhibitor TMC435 to standard pegylated interferon/ribavirin therapy led to high rates of sustained virological response for both treatment-naive hepatitis C patients and prior non-responders, according to data released last week at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011).
AASLD 2011: High Sustained Response Rates with PSI-7977 Plus Pegylated Interferon/Ribavirin
- Details
- Category: HCV Treatment
- Published on Tuesday, 22 November 2011 00:00
- Written by Liz Highleyman
Adding the hepatitis C virus (HCV) polymerase inhibitor PSI-7977 to pegylated interferon plus ribavirin produced a 91% cure rate for previously untreated patients with hard-to-treat HCV genotype 1, according to results from the PROTON study presented this month at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) in San Francisco.
AASLD 2011: BI 201335 Performs Well with Standard Therapy
- Details
- Category: HCV Treatment
- Published on Tuesday, 15 November 2011 00:00
- Written by Liz Highleyman
Once-daily BI 201335 added to pegylated interferon/ribavirin for 24 weeks produced consistently high SVR rates across difficult-to-treat chronic hepatitis C patient subgroups, according to findings from the SILEN-C1 study presented at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) last week in San Francisco. A follow-up study showed that rapid responders did equally well with 12 or 24 weeks of treatment.
More Articles...
- AASLD 2011: HCV Direct-Acting Antivirals Boost Interferon Response Rates
- AASLD 2011: Do Hepatitis C Patients with Cirrhosis Benefit from Adding Telaprevir?
- AASLD 2011: Adding Tenofovir to Entecavir Offers No Additional Benefit for Hepatitis B Patients
- AASLD 2011: Telaprevir Improves Hepatitis C Treatment Response for HIV/HCV Coinfected People
Web Design and Development by